HCPCS Level II code Q2026 denotes a 0.1 ml injection of Radiesse, a calcium hydroxylapatite dermal filler used for soft tissue augmentation and cosmetic volumizing. This code is used to bill for the product unit rather than the administration-only service and matters nationally as the use of injectable aesthetic products continues to grow across outpatient dermatology, plastic surgery, and medical aesthetic settings. Payers assess product-level codes like Q2026 for coverage, coding consistency, and pricing transparency.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents and where it is typically used, plus an outline of what to expect in deeper sections: payer coverage and policy positions, coding and billing considerations, and clinical context for product use. The publication also summarizes benchmarks and common modifier usage patterns where available. National stakeholders — providers, coders, and payers — can use the information to align coding practice, understand billing implications for dermal filler product units, and locate payer-specific policy references. Data not available in the input is noted where applicable.